

# Cumulative Index 1989

## Volume 5

---

<i>February</i>	GERIATRIC DERMATOLOGY, pages 1-257
<i>May</i>	SLEEP DISORDERS IN THE ELDERLY, pages 259-424
<i>August</i>	NEW DEVELOPMENTS IN NEUROPSYCHOLOGICAL EVALUATION, pages 425-638
<i>November</i>	HYPERTENSION, pages 639-858

---

*Note:* Page numbers for complete issues and articles appear in **boldface** type.

- Abdomen, examination of, in hypertension, 728
- Abdominal fat, and hypertension, 659
- Acetylcholine synthesis, decreased, in Alzheimer's disease, 434
- Acne rosacea, 200-201
- Acral lentiginous melanoma, 175
- Acrochordons, 190-191
- Actinic elastosis, 223, 236  
histopathology of, 134-135
- Actinic keratoses, 229-230  
clinical features of, 163-164  
histology of, 164  
malignant progression of, 162-166  
treatment of, 165-166
- Action, hierarchical organization of, 500-503
- Activities of daily living scales, for independent living skills assessment, 472  
of quality of life, 708
- Adiposity, and hypertension, 658-659
- Adrenal hyperplasia, hyperaldosteronism vs, 759
- Adrenergic inhibitors, adverse effects of, 693  
central, cost of, 832-833  
for hypertension, 808-809  
effect on concomitant disease, 700  
in renal disease, 821-822
- Adrenergic receptors, imbalance of, in isolated systolic hypertension, 667
- Affect, assessment of, 441-459
- ACE products, formation of, in aging, 12
- Age(ing), amino acid racemization in, 11-12  
and impotence, 301-314  
association with blood pressure, 640-644  
biologic, molecular basis of, 1-21  
changes in sleep with, 275-287  
cutaneous carcinogenesis in, 161-162  
dysdifferentiation theory of, 13-14  
effect on epidermal immune function, 149-160  
fibroblast model of, 23-25  
importance of appearance in, 213-214  
in-vitro studies of, 23-40  
in-vivo correlations with, 27  
lymphokines in, 151-158  
nonenzymatic glycosylation in, 12-13  
normal, cognitive decline in, 532-533  
ecological memory assessment in, 583-594  
effect on personality, 443  
of United States population, dermatologic implications of, 41-51  
photoaging vs, histologic comparisons of, 235-239  
physiologic, and appearance, 215  
cutaneous clues to, 123  
sun-induced, 223-233  
chemical determinations of, 226-227  
microscopy of, 225-226  
vascular system pathology with, 662-665  
wound healing and, 183-189
- Aging skin, morphology of, 53-67
- Agnosia, as memory disorder, 569
- Airway collapse, and sleep apnea, 318-319
- Airway obstruction, and snoring, 349
- Alcohol, and impaired mental abilities, 388

- Alcohol (*Continued*)  
 effect on sleep-related respiratory disturbance, 401
- Alcohol restriction, for hypertension, 770
- Alopecia, androgenetic, 205-207
- Alpha-blockers, adverse effects of, 693  
 cost of, 832-833  
 for hypertension, effect on concomitant disease, 699  
 in renal disease, 822
- Alzheimer's disease, and indifference to disability, 447  
 assessment of, 536. See also *Alzheimer's Disease Assessment Scale*.  
 neuropsychological, pathologic validity of, 428-431  
 behavioral markers in, 436  
 biochemistry of, 434-438  
 biomarkers of, search for, 296  
 cognitive decline in, measurement of, 531  
 daytime sleep in, 295  
 dementia in, 533-534  
 depression in, 445  
 disturbed sleep in, neural basis for, 290  
 Huntington's disease vs, 602  
 Wechsler Memory Scale-Revised for, 611-632  
 intrusion errors in, 624-627  
 location of lesions in, 436  
 memory disorders in, 572  
 mental status examinations in, 555  
 neuropathological changes in, 425-440  
 neuropsychological changes in, 425-440  
 neurotransmitters in, 434-438  
 nighttime awakening in, 294  
 nonsomatic treatment of, 427  
 personality profile in, 456-457  
 REM sleep in, 292-293  
 scoring systems for, 291  
 sleep in, 289-299  
 changes in, 263  
 patterns of, 290-294  
 stages of, 293  
 sleep/wake patterns in, 289-299, 295
- Alzheimer's Disease Assessment Scale, correlation with disease duration, 556  
 for cognitive function assessment, 555  
 for mood assessment, 453-454
- Amadori product, formation of, in aging, 12
- Amino acid racemization, in aging, 11-12
- Aminoguanidine, anti-aging effects of, 13
- Amnesia, bimodal, 570-571  
 defective insight with, 482  
 dementia vs, on Wechsler Memory Scale-Revised, 614  
 diencephalic, 569-570  
 drug-induced, 397  
 global, transient, 571  
 post-traumatic, 508  
 psychogenic, 572  
 types of, 569-572
- Amyloid deposits, in Alzheimer's disease, 430-433
- Angina pectoris, antihypertensive agents in, 814  
 metoprolol for, 815  
 with snoring, 350
- Angioplasty, for renovascular hypertension, 764-765
- Angiotensin-converting enzyme inhibitors, adverse effects of, 693  
 cost effectiveness of, 837-839  
 cost of, 833-834  
 for hypertension, 807-808  
 effect on concomitant disease, 699  
 in congestive heart failure, 817  
 in coronary artery disease, 816  
 in diabetes mellitus, 820  
 in renal disease, 822  
 quality of life with, 709-712
- Anguish, with brain lesions, 442
- Angular cheilitis, 199-200
- Animals, age-related sleep changes in, 363-369  
 relations to human aging, 367-368  
 physiologic function in, relationship to sleep, 368-369
- Anomia, as memory disorder, 568
- Anosognosia, in brain injury, 483  
 in dementia, 480
- Antidepressants, for depression-associated sleep disturbances, 268-269
- Antihistamines, and drug-induced sleepiness, 398
- Antihypertensive agents, adverse effects of, 691-702  
 quality of life with, 696-697  
 reduction of, 701  
 ambulatory monitoring of, 745  
 and drug-induced sleepiness, 398  
 choice of, 803-811  
 classes of, 804-809  
 clinical trials of, 692-696  
 cost effectiveness of, 834-835  
 cost of, 832-834  
 disease aggravation by, 697-698  
 effect on concomitant disease, 699-700, 813-828  
 functional impairment with, 697-698  
 in chronic obstructive pulmonary disease, 818  
 in congestive heart failure, 817-818  
 in depression, 823-824  
 in diabetes mellitus, 818-820  
 in left ventricular hypertrophy, 816-817  
 in renal disease, 820-823  
 in stroke, 823  
 limitations of, 698  
 long-term use of, safety in, 700  
 physician evaluation of, 705  
 quality of life with, 703-715

- side effects of, 692-700
- Antioxidants, exogenous, in cellular protection against oxidative free radical damage, 9-11
- Anxiety, and performance speed, 510
- Aortic coarctation, and hypertension, 754
- Aortic insufficiency, blood pressure measurement in, 723
- Aortic rigidity, increased, in hypertension, 663
- Apathy, with frontal lobe damage, 503
- Apnea, central, definition of, 315
  - in sleep loss recovery, 412
  - mixed, definition of, 315
  - obstructive, airflow pressures and, 300
  - definition of, 315
  - sleep. See *Sleep apnea*.
- Apnea index, 350
  - and mortality, 356
- Appearance, psychology of, in elderly, 213-222
- Appetite, assessment of, in dietary hypertension therapy, 778
- Arousal threshold, in sleep loss recovery, 412
- Arrhythmias, with sleep apnea, 322, 350
- Arterial stiffness, and pseudohypertension, 725-726
- Arteriography, in renovascular hypertension, 762
- Ascorbate, in cellular protection against oxidative free radical damage, 10
- Asteatosis, 196-197
- Asthma, antihypertensive agents in, 818
- Atenolol, cost of, 833
  - for hypertension, COOPE study of, 687-689
  - in renal disease, 821
  - quality of life with, 711
  - side effects in, 696
- Atherogenesis, acceleration of, with hypertension, 663
- Atherosclerosis, antihypertensive agents in, 814
  - blood pressure measurement in, 723
- Atrial natriuretic peptides, in congestive heart failure, 817-818
- Attention, assessment of, 614-621
  - decreased, in dementia, 492
  - memory vs, on Wechsler Memory Scale-Revised, 613
  - role in memory, 567
- ATTMH. See *Australian Therapeutic Trial in Mild Hypertension*.
- Australian Therapeutic Trial in Mild Hypertension, 685-687
  - design of, 685-686
  - results of, 686-687
  - treatment effectiveness in, 831
- Autoantibodies, increase in, age-related, 150
- B cells, and humoral immunity, 150-151
- Baldness, male-pattern, 206
- Baroreceptor reflexes, impaired, 666
  - in hypertension, 663
- Barrier properties, of skin, 115-117, 121
- Barthel Index, for independent living skills assessment, 468
- Basal cell carcinoma, 166-167
- Basal lamina, in aging skin, 88
- Beck depression inventory, for mood assessment, 449-450
- Behavioral assessment, in dietary hypertension therapy, 778-779
- Behavioral interventions, for hypertension, 777
  - rationale for, 792-794
- Behavioral Problem Checklist, for caregivers, 465
- Behavioral slowing, with aging, 504-506
- Benzodiazepines, and drug-induced sleepiness, 397
  - effect on sleep-related respiratory disturbance, 400
- Beta-Blocker Heart Attack Trial, drug side effects in, 695
- Beta-blockers, adverse effects of, 693
  - cost of, 833
  - for hypertension, 806-807
    - effect on concomitant disease, 699
    - reduced efficiency of, 663
  - in asthma, 818
  - in chronic obstructive pulmonary disease, 818
  - in coronary artery disease, 814-815
  - in depression, 823-824
  - in diabetes mellitus, 819
  - in renal disease, 821
  - quality of life with, 706, 710-711
- Bilirubin, in cellular protection against oxidative free radical damage, 10
- Biologic aging, molecular basis of, 1-21
- Blessed, Tomlinson, Roth Dementia Scale, correlation with Alzheimer's Disease Assessment Scale, 556
  - for personality assessment, 451-452
- Blood count, complete, in hypertension, 728
- Blood flow, in skin, age-related changes in, 117-118
- Blood pressure, ambulatory monitoring of, 733-751
  - accuracy of, 739-741
  - automated, 737-739
  - circadian rhythms of, 746
  - correlation with office measurements, 739-741, 743
  - cost effectiveness of, 747-748
  - data analyses of, 741-743
  - diagnostic implications of, 743-747
  - equipment for, 735-739
  - errors in, detection of, 741-742

- Blood pressure (*Continued*)  
 ambulatory monitoring of, practicality of, 735, 747-748  
   prognostic implications of, 745  
   technician training in, 741  
   therapeutic implications of, 745  
 association with age, 640-644  
 classification of, 718  
 factors affecting, 642-646  
 high. *See Hypertension.*  
 intra-arterial, cuff pressure vs, 724-725  
 measurement of, ambulatory. *See under ambulatory monitoring of.*  
   follow-up criteria for, 719  
   home, self-initiated, 735-737  
   indirect, accuracy of, 724-726  
   need for repetition of, 723-724  
   office, correlation with ambulatory monitoring, 743  
   insufficiency of, 734-735  
   technical considerations in, 721-723  
   systolic, association with mortality, 648  
   diastolic vs, as cardiovascular risk predictors, 650  
   variability of, 719-720, 734-735  
   age-related increase in, 724  
 Blood pressure manometers, technical considerations in, 721-723  
 Blood sugar, fasting, association with blood pressure, 643  
 Blood urea nitrogen, measurement of, in hypertension, 728  
 Blue nevus, 94  
 Brain injury, etiologies of, differentiation by age, 605  
   focal, mania with, 445-446  
   prognosis following, 448  
 Breaking strength, of incisional wounds, 184-185  
 Breathing, sleep-disordered, clinical evaluation of, 323-324  
   in depression, 267  
 Browning, nonenzymatic, in aging, 12  
 Bullous pemphigoid, 193  
 Bumetanide, in renal disease, 821  
 Burden Interview, for caregivers, 464  
 Buttock skin, electron microscopy of, 81-84  
  
 Caffeine, and drug-induced insomnia, 398-399  
 Calcium, in hypertension, 661-662, 728  
 Calcium antagonists, adverse effects of, 693  
   for hypertension, effect on concomitant disease, 699  
 Calcium channel blockers, cost effectiveness of, 837-838  
   cost of, 833-834  
   for hypertension, 807  
   in congestive heart failure, 817  
   in coronary artery disease, 816  
   in diabetes mellitus, 820  
   in renal disease, 822-823  
 Caloric intake, assessment of, in dietary hypertension therapy, 778  
 Cambridge Mental Disorders of the Elderly Examination, in dementia, 536  
 Capillary, arterial, vascular wall thickening in, 82  
   venous, normal appearance of, 79  
 Captopril, cost of, 833  
   annual, 837  
   for hypertension, 808  
   in renal disease, 822  
   quality of life with, 706, 710-711  
 Carbohydrate intake, assessment of, in dietary hypertension therapy, 779  
 Carcinogenesis, cutaneous, and aging, 161-162  
 Carcinoma, basal cell, 166-167  
   squamous cell, progression of actinic keratoses to, 162-166  
 Cardiac system, in hypertension, 658  
 Cardiopulmonary dysfunction, in sleep apnea, 321  
 Cardiovascular disease, hypertension and, 651  
   mortality from, 640, 650  
   in Hypertension Detection and Follow-up Program, 680-681  
   quality of life with, 704  
 Cardiovascular drugs, and drug-induced insomnia, 399  
 Caregiver burden, with dementia, assessment of, 464-465  
 Catalase, in cellular protection against oxidative free radical damage, 6-7  
 Catecholamines, urinary, in hypertension, 757  
 Category Test, age-related decrements in, 599-600  
 Cations, role in hypertension, 661-662  
 Cats, age-related sleep changes in, 366-367  
 Cautiousness, increase with aging, 505-506  
 Ceiling effects, in cognitive measurement scales, 522-523  
 Cell-mediated immunity, age-related changes in, 151  
 Cell migration, in wound healing, 186  
 Cell proliferation, in wound healing, 185  
 Cellular aging, in vivo-in vitro correlations of, 27  
 Cellular differentiation, alterations in, with aging, 15  
 Cellular senescence, genetic control of, 29-31  
   in nonfibroblast lines, 25-26  
 Center for Epidemiological Studies Depression Scale, of quality of life, 708  
 Cerebrovascular disease, blood pressure and, 647

- mortality from, 648, 650
- Ceruloplasmin, in cellular protection against oxidative free radical damage, 10
- Cheilitis, angular, 199-200
- Cherry hemangioma, 191
- Chest radiography, in hypertension, 729
- Chloride, measurement of, in hypertension, 728
- Chlorthalidone, for hypertension, 804-805
  - in coronary artery disease, 815
  - quality of life with, 711
- Choking, in sleep apnea, 321
- Cholesterol, in hypertension, 728
  - with antihypertensive therapy, 694
- Cholinergic neurotransmitters, in Alzheimer's disease, 434
- Chondrodermatitis nodularis helices, 192
- Choroid, pigment cells in, 105
- Chronic obstructive pulmonary disease, antihypertensive agents in, 818
- Chymotrypsin, effect on skin aging, 85
- Circadian rhythm, 331-346
  - amplitude of, age and, 332-333
  - free-running, in elderly, 334-339
    - sleep during, 340-342
  - masking effects in, 332
  - phases of, age and, 333
    - tolerance to changes in, 342-343
  - psychological, 343
  - relationship to sleep, in animals, 369-370
  - unmasking studies of, in elderly, 333-334
- Circadian system, 331-332
- Circulatory disease, death rates from, 639
- Clonidine, cost of, 833
  - for hypertension, 809
    - effect on concomitant disease, 700
    - in diabetes mellitus, 820
    - in renal disease, 822
    - quality of life with, 710
- Cognition. See also under *Cognitive*.
  - controlled vs automatic processing in, 537
- Cognitive ability, fluid vs crystallized, 536-537, 597
  - mental status examinations of, correlation of, 557-559
- Cognitive deficits, assessment of, instruments for, 534-536
  - differential diagnosis of, Halstead-Reitan Test Battery for, 601-602
  - in Alzheimer's disease, charting of, 537-538
    - neurophysiological correlates of, 431-433
  - in dementia, measurement of, 519-530
- Cognitive function, brief measures of, 552
  - general screening tests of, 553-555
  - interactions with sleep, in animals, 371-375
  - neuropsychological assessment of, 441
- Cognitive mental status examinations, 545-564
- Cognitive scales, administration of, 528-529
  - application of, 529
  - difficulty level of, 527-528
  - for demented populations, 521-523
  - for normal and demented populations, 524-529
    - for normal populations, use in dementia, 519-521
  - of quality of life, 709
  - types of items for, 524-527
- Collagen(s), age-related changes in, 60-63, 127-147
  - biochemistry of, 128-131
  - categories of, 128
  - decrease in, with photoaging, 226, 238, 241
  - degeneration of, in actinic elastosis, 85
  - metabolism and synthesis of, with aging, 135-138
  - structure of, 129
  - synthesis of, in wound healing, 186
    - rate of, age-related changes in, 136
- Colloid milia, 230-231
- Communication, assessments of, 470-471
- Comprehension subtest, for judgment assessment, 490
- Concentration, assessment of, on Wechsler Memory Scale-Revised, 616
  - difficulties in, snoring and, 386
  - role in memory, 567
- Confusional states, memory disorders in, 573
- Contact dermatitis, 194-195
  - prevalence rates for, 47
- Contact sensitivity, in aging skin, 155-156
- Continuous positive airway pressure, for sleep apnea, 325
- Contraction, of open wounds, 183-184
- COOPE study, description of, 687-689
  - design of, 687
  - results of, 688-689
  - treatment effectiveness in, 831
  - treatment schedule for, 687-688
- Coronary artery spasm, beta-blockers in, 814-815
- Cornell Scale for Depression in Dementia, 452-453
- Corneocytes, age-related changes in, 116
  - normal turnover of, 121-123
- Coronary artery disease, antihypertensive agents in, 813-816
- Cosmetics, psychology of, 218-221
- Cost effectiveness, definition of, 834
- Counseling, group, in Heartsavers Lifestyle Management Program, 796
- Creatinine, in hypertension, 728, 759
  - with antihypertensive therapy, 694

- Cultural practices, assessment of, in dietary hypertension therapy, 779
- Cushing's disease, and hypertension, 754
- Cushing's syndrome, and hypertension, 759
- Cutis laxa, lesions of, 139-143
- Cyclin, in replicating cells, 30
- Cysts, dermal, formation of, with aging, 85  
proliferation of, ultraviolet-induced, 241, 243
- Cytoheterogeneity, of aging skin, 56-58
- Cytokines, effect of aging on, 151-152
- Daytime functioning, circadian effects on, 343
- Delayed Nonmatching-to-Sample test, for ecological memory assessment, 587
- Dementia(s), cognitive deficits in, measurement of, 519-530  
differential diagnosis of, 614-621  
  EEG sleep in, 262-264  
  identification of, 614-621  
  in Alzheimer's disease, 533-534  
  intrusion errors in, 621-627  
  judgment and, 491-495  
  level of, and independent living skills, 428  
  memory disorders in, 572  
  mental status examinations in, correlation of, 557-559  
  severe, assessment of, 536-540  
  sleep apnea and, 353  
  sleep deprivation in, 265-266  
  sleep stages in, 411  
    psychometric correlates of, 384  
  with secondary depression, sleep changes in, 264
- Dementia Mood Assessment Scale, 453
- Dementia Rating Scale, for cognitive deficit measurement, 521-522
- DeMorgan's spots, 191
- Denial, in dementia, 482  
with brain lesions, 442
- Depressants, and drug-induced insomnia, 398-399  
and drug-induced sleepiness, 397
- Depression, and memory impairment, 572  
and sleep deprivation, 417  
antihypertensive agents in, 823-824  
differential diagnosis of, EEG sleep in, 262-264  
drug-induced, 445  
in disease states, 444-445  
late-life, 259-273  
  EEG sleep in, 260-262  
  irreversibility hypothesis of, 270  
  maintenance therapy for, 264-267  
  recurrence of, prediction of, 267  
  treatment of, 268-269  
reduced REM latency in, 417  
sleep changes in, 263, 411  
sleep deprivation in, 265-266  
sleep-disordered breathing in, 267  
with aging, 506-507  
with brain lesions, 442
- Dermal/epidermal junction, of aging skin, 56-57
- Dermatitis, contact, 194-195  
prevalence rates for, 47  
exfoliative, 194  
seborrheic, prevalence rates for, 47  
with declining sebum secretion rate, 113-114  
stasis, 203-204
- Dermatologic disease, population demographics and, 45-49
- Dermatologists, utilization of, 49-50
- Dermatology, geriatric, 1-252
- Dermatophytosis, prevalence rates for, 46
- Dermatosis papulosa nigra, 190
- Dermis, aging, changes in, 133-139  
connective tissue biochemistry of, 127-147  
  morphology of, 59-60  
  photoaged, repair of, 246-247  
  structure of, 133-134
- Desynchronization, spontaneous internal, in free-running conditions, 336-337  
tendency toward, age and, 339-340
- Diabetes mellitus, antihypertensive agents in, 818-820  
skin changes with, electron microscopy of, 84
- Dietary changes, for hypertension, 770, 777  
precautions in, 781-782  
rationale for, 792-794  
in Heart Savers Lifestyle Management Program, 796  
individualized, for hypertension, 783-784
- Dietary history, assessment of, in dietary hypertension therapy, 778-779
- Dietary Intervention Study of Hypertension, 773-775
- Difference scores, on Wechsler Memory Scale-Revised, 617-619
- Diltiazem, cost of, 833  
annual, 837  
for hypertension, 807  
in coronary artery disease, 816
- DISH. See *Dietary Intervention Study of Hypertension*.
- Disinhibition, in dementia, 493
- Distractibility, and performance speed, 510
- Diuretics, adverse effects of, 693  
cost of, 832-833  
annual, 837  
for hypertension, 804-806  
effect on concomitant disease, 699  
in congestive heart failure, 817  
in depression, 824

- in diabetes mellitus, 819
- in renal disease, 821
- quality of life with, 710
- DNA synthesis, and cellular senescence, 30
- Down's syndrome, similarities to Alzheimer's disease, 430-431
- Drug(s), and depression, 445
  - and mania, 446
  - and sleep disorders, in aging, 395-404
  - pharmacokinetics of, aging and, 395-397
- Drug reactions, in Hypertension Detection and Follow-up Program, 680-681
- Drug therapy, memory disorders with, 573
- Dry skin, 196-197
  - with declining sebum secretion rate, 113
- Dysdifferentiation theory, of aging, 13-14
- Dysphoria, late-life, 260
  
- Eating, and blood pressure, 720, 722
- Echocardiography, in hypertension, 729
- Eczema, prevalence rates for, 47
- Eczema craquelé, 196-197
- Education, in hypertension therapy, 777
  - level of, and Halstead-Reitan Test Battery performance, 601
- Elastase, effect on skin aging, 85
- Elastic fibers, cutaneous, 69-78
  - abnormalities of, age-related, 73-77
    - causes of, 84
    - lesions from, 139-143
  - actinic damage to, 72-73, 137
  - biochemistry of, 131-133
    - in aging, 137-139
  - degradation of, in aging skin, 86
  - enzymatic digestion of, 77-78
  - formation of, 71-72
  - hyperplasia of, ultraviolet-induced, 244
  - increase in, with photoaging, 237
  - microscopy of, 70-71
- Elastin, accumulation of, in skin, 139-142
  - age-associated alterations in, 63-65, 127-147
    - biosynthesis of, in aging skin, 86
    - increase of, sun-induced, 226
    - structure of, 132
- Elastoderma, lesions of, 139-142
- Elastoidosis, nodular, 230-231
- Elastosis, actinic, 223, 236
  - histopathology of, 134-135
  - experimental, 227-228
  - infrared-induced, 244-245
  - senile, 223
  - ultraviolet-induced, 240, 242, 244-245
- Elderly, cosmetic therapy for, 219-221
  - cutaneous malignant melanoma in, 171-181
  - hypertension in, basic evaluation of, 717-732
  - memory in, assessment of, 565-581
  - nonmelanoma skin cancers in, 161-170
  - psychology of appearance in, 213-222
  - sebum secretion rate in, 110
  - severely impaired, neuropsychological assessment of, 531-543
  - skin problems in, 189-211
- Electrocardiography, in hypertension, 729
- Electroconvulsive therapy, for depression-associated sleep disturbances, 269
- Electroencephalography, for sleep evaluation, 275
  - in rats, 365
- Electron microscopy, of elastic fiber network of skin, 70-71
  - of sun-induced aging, 226
- Embryogenesis, dermal pigment cells during, 93-94
- epidermal melanocytes during, 95-97
- Enalapril, cost of, 833
  - annual, 837
  - in renal disease, 822
  - quality of life with, 711
- Endocrine disorders, and impotence, 309-310
- Environmental factors, in hypertension, 657-662
- Epidermal thymocyte-activating factor (ETAF), age-related changes in, 156-157
- Epidermis, aging, immune function of, 149-160, 152-154
  - morphology of, 53-59
  - normal turnover of, 121-123
- Epinephrine excretion, correlation with systolic hypertension, 667
- Epithelialization, of open wounds, 184
- Erection, capability of, with aging, 303-310
  - nocturnal, 307
  - sleep-related, changes in, 304-305
  - vascular mechanism of, 306
- Erythema, intermittent, 200-201
- European Working Party on High Blood Pressure in Elderly, clinical drug trials in, 694
  - data analysis of, 683
  - description of, 682-685
  - malignant hypertension in, 684
  - mortality rate in, 684
  - participant characteristics of, 682
  - results of, 683-685
  - sample size of, 683
  - treatment cost effectiveness in, 836-838
  - treatment effectiveness in, 830
  - treatment schedule for, 682
- EWPH. See *European Working Party on High Blood Pressure in Elderly.*
- Exercise, for hypertension, 777, 782
- Exercise training, for hypertension, 794-795



- Exercise training (*Continued*)  
 in Heart Savers Lifestyle Management Program, 796  
 Exfoliative dermatitis, 194  
 Extensor forearm skin, electron microscopy of, 80-82  
 Eye(s), examination of, in hypertension, 727  
 pigment cells of, 103-105
- Facial hair, excessive, 207  
 Fatigue, in older adults, in neuropsychological testing, 596  
 Fiber intake, assessment of, in dietary hypertension therapy, 779  
 Fibroblast(s), effect of growth factors on, 28  
 Fibroblast model, of aging, 23-25  
 Fibroepithelial polyp, 190-191  
 Finger tapping test, for neuropsychological assessment, 514  
 First-Last Name Association, for ecological memory assessment, 587  
 Floor effects, in cognitive measurement scales, 520-521  
 Flurazepam, effect on sleep-related respiratory disturbance, 400  
 Food preferences, assessment of, in dietary hypertension therapy, 778  
 Forgetting, rates of, measures of, 614-621  
 Free radical(s), and differential gene expression, 14-16  
 Free radical damage, oxidative, cellular protective mechanisms against, 6-11  
 Free radical theory, of biologic aging, 4-6  
 Frontal lobe injury, and indifference to disability, 446-447  
 inappropriateness with, 447  
 Functional Communication Profile, 470  
 Furosemide, cost of, 833  
 in renal disease, 821
- GABA, reduced, in Alzheimer's disease, 437  
 Gastrointestinal changes, age-related, and drug absorption, 395  
 Gene expression, differential, free radicals and, 14-16  
 General Psychological Well-Being Scale, of quality of life, 708  
 Genetic control, of cellular senescence, 29-31  
 Geriatric Depression Scale, 450, 507  
 Geriatric dermatology, 1-252  
 Geriatric Mental Status Schedule, in dementia, 535  
 Global Deterioration Scale, in dementia, 536  
 Glucocorticoids, effect on fibroblasts, 28  
 Glucose intolerance, in hypertension, 643, 728  
 with antihypertensive therapy, 695  
 Glutathione system, in cellular protection against oxidative free radical damage, 7-8  
 Glycine, in collagen polypeptides, 128-129  
 Glycosylation, nonenzymatic, in aging, 12-13  
 Grafting, skin, and reversal of sun-induced aging, 227  
 Graying, of hair, 204-205  
 Grip strength test, for neuropsychological assessment, 513-514  
 Grooved Pegboard, for neuropsychological assessment, 512-513  
 Ground substance, of skin, changes with photoaging, 238  
 Growth factors, role in aging, 28-29  
 GSH peroxidase, in cellular protection against oxidative free radical damage, 9  
 GSH reductase, in cellular protection against oxidative free radical damage, 8
- Hair, 97-100  
 changes in, in elderly, 204-207  
 embryogenesis of, 97-99  
 facial, excessive, 207  
 graying of, 204-205  
 loss of, androgenetic, 205-207  
 pigment cells in, in postnatal life, 99-100  
 Halstead Impairment Index, effect of age on, 597  
 Halstead-Reitan Test Battery, age-related normative data for, 598-600  
 reliability in, 603-604  
 test time in, 602-603  
 use with older adults, 595-610  
 validity in, 604-606  
 Hamilton Depression Scale, for mood assessment, 448-449  
 Hayflick model, of aging, 23  
 HDFF. See *Hypertension and Detection Follow-up Program*.  
 Head injury, closed, effects of, 508  
 Health practices, assessment of, in dietary hypertension therapy, 778  
 Health services, cost of, 44-45  
 utilization of, dermatological implications of, 49-50  
 Heart, examination of, in hypertension, 728  
 Heart disease, coronary, hypertension and, 647, 651  
 ischemic, mortality in, 648, 650  
 Heart failure, congestive, antihypertensive agents in, 817-818  
 blood pressure and, 647



- Heartsavers Lifestyle Management Program, for hypertension, 796-798  
 Heliodermatitis, with photoaging, 237-238  
 Hemangioma, cherry, 191  
 Hemodialysis, in renal disease, 823  
 Herpes zoster, 201-202  
 High blood pressure. *See* Hypertension.  
 Home Visit Assessment, of independent living skills, 473  
 Homeostasis, deficiencies of, and hypertension treatment, 691  
 Hopkins Brief Symptom Inventory, of depression, 507  
 Hormonal factors, in hypertension, 658, 754  
 Humoral immunity, B cells and, 150-151  
 Huntington's disease, Alzheimer's disease vs, 602  
     Wechsler Memory Scale-Revised for, 611-632  
         intrusion errors in, 624-627  
 Hydralazine, adverse effects of, 693  
     cost of, 833  
         annual, 837  
     for hypertension, 808  
         effect on concomitant disease, 700  
 Hydrochlorothiazide, cost of, 833  
     for hypertension, 805  
     in coronary artery disease, 815  
     metoprolol vs, 695  
     quality of life with, 710-711  
 Hydrocortisone, effect on fibroblasts, 29  
 Hydroxylsine, in collagen polypeptides, 129-130  
 Hydroxyproline, in collagen polypeptides, 129  
 Hyperaldosteronism, and hypertension, 754, 757-759  
 Hyperglycemia, association with blood pressure, 643, 728  
 Hyperkeratoses, seborrheic, 190  
 Hyperparathyroidism, and hypertension, 754, 759  
 Hyperpigmentation, of aging skin, 56  
 Hypersomnolence, sleep-disordered breathing and, 322, 324  
 Hypertension, 639-840  
     age-related factors in, 658  
     ambulatory monitoring of, 733-751  
     central nervous system effects of, 705-706  
     classifications of, 645  
     comorbid problems with, antihypertensive agents for, 813-828  
     confirmation of, 718-726  
     definition of, 718-719  
     diastolic, isolated, risk of, 652  
     differential diagnosis of, 726  
     drug therapy models for, cost effectiveness of, 835-839  
     electrocardiographic abnormalities with, mortality in, 805  
     emergency situations in, 719  
     epidemiology of, 639-655  
     episodic, ambulatory monitoring in, 746  
     etiology of, 657-662  
     evaluation of, 717-732  
     impaired mental abilities with, 388  
     mild, treatment of, 677  
     mortality from, 648, 649, 651  
     nondrug therapy for, 770, 791-802  
         blood lipid changes in, 798  
         blood pressure changes in, 797  
         difficulties of, 798-800  
         disadvantages of, 798-800  
         rationale for, 792-794  
     pathophysiology of, 657-674  
     prevalance of, 644-646  
     renovascular, screening tests for, 761-762  
     risks of, 646-652  
     secondary, 753-768  
         causes of, 753-755  
         diagnostic evaluation of, 756-762  
         endocrine causes of, 757-759  
         pragmatic strategy for, 765-766  
         prevalence of, 754-755  
         therapeutic approaches to, 762-765  
     sodium restriction in, 769-789  
     stepped care of, benefits of, 681  
         cost effectiveness of, 836-838  
         referred care vs, 677-679  
     systolic, isolated, 665-668  
     technical considerations in, 721-723  
     treatment of, adverse effects of, 691-702  
         clinical trials of, 675-690  
         effectiveness of, 830-832  
         physiologic changes influencing, 691-692  
         recommendations in, 769-770  
     vascular system pathology with, 662-665  
     weight reduction in, 769-789  
     with sleep apnea, 322, 350-351  
     with snoring, 350  
 Hypertension Detection and Follow-up Program, blood pressure goal status in, 679  
     clinical drug trials in, 692-694  
     description of, 676-681  
     design features of, 676-677  
     effectiveness of, 830-831  
     mortality in, 680-681  
     participant characteristics of, 678  
     results of, 677-679  
     side effects of, 680  
 Hyperthyroidism, blood pressure measurement in, 723  
 Hypokalemia, in hypertension, 757  
 Hypotension, postprandial, ambulatory monitoring in, 746  
 Hypoxemia, in apnea, effects of, 387  
  
 Immune function, epidermal, effect of age on, 149-160

- Impotence, aging and, 301-314  
   definition of, 302-303  
   endocrine disorders and, 309-310  
   etiology of, 303  
   evaluation of, 310-311  
   in elderly, prevalence of, 302  
   neurologic changes and, 308-309  
   pharmacologic causes of, 309  
   psychologic disorders and, 310  
   treatment of, 310-311  
   vascular changes and, 305-308
- Impulsivity, in dementia, 493
- Inappropriateness, with central nervous system dysfunction, 447
- Independent living skills, assessment of, 461-475  
   approaches to, 462-463  
   instruments for, 465-473  
   issues in, 461-465  
   mental status evaluations and, 463-464  
   purposes of, 463  
   definition of, 461  
   insight assessment and, 485
- Index scores, on Wechsler Memory Scale-Revised, 616-617
- Indifference, to physical disability, with neurologic disease, 446-447
- Inflammatory response, age-related decline in, 118-119
- Infrared radiation, and photoaging, 243-246
- Insight, assessment of, methods of, 486-488  
   complexity of, 487  
   definition of, 480  
   mental status assessment of, 477-496  
   theoretical conceptions of, 480-488
- Insomnia, drug-induced, and aging, 398-399  
   sleep-disordered breathing and, 323  
   sleep stages in, 411  
   subjective reports of, 347  
   with late-life depression, treatment of, 268-269
- Instrumental Activities of Daily Living Scale, for independent living skills assessment, 462, 468-469
- Integumental reactivity, age-related decline in, 118-119
- Intelligence, correlation with sleep measures, 382  
   crystallized vs fluid, 536-537, 597  
   role in memory, 568
- Interleukins, effect of aging on, 151-152
- Interpersonal Support Evaluation List, of quality of life, 707
- INTERSALT study, 660
- Intertrigo, 198-199
- Intrusion errors, analysis of, 625  
   as marker of dementia, 621-627  
   on Wechsler Memory Scale-Revised, 617-619
- Itching, 195-196
- Ito, nevus of, 94-95
- Judgment, and dementia, 491-495  
   definition of, 488-489  
   mental status assessment of, 477-496
- Katz Index of ADL, for independent living skills assessment, 467
- Kenny Self-Care Evaluation, for independent living skills assessment, 467
- Keratinization, of aging skin, 57-58
- Keratinocytes, cellular senescence of, 26  
   effect of growth factors on, 28
- Keratoacanthoma, 167-168
- Keratoses, actinic, 163-166, 229-230  
   seborrheic, 189-191
- Kidney. *See also under Renal; Reno-*  
   function of, decreased, drug elimination with, 396  
   revascularization of, for renovascular hypertension, 764
- Korsakoff's syndrome, amnesia in, 569-570
- Labetolol, cost of, 833  
   for hypertension, 808  
   in renal disease, 821
- Laboratory studies, in hypertension, 728-730
- Lacunae, dermal, formation of, with aging, 85
- Langerhans cells, in immune response, effect of aging on, 153  
   reduced density of, age-related, 155-156
- Language impairment, in Alzheimer's disease, 534
- Late life, sleep and depression in, 259-273
- Laterality, neuropsychological assessment of, 510-511
- Learning, types of, 566-568
- Left ventricular hypertrophy, 729  
   antihypertensive agents in, 816-817
- Left ventricular mass index, correlation with blood pressure, 744
- Leg movements, in sleep loss recovery, 412  
   periodic, in sleep, 356-357  
   effect of drugs on, 401-402
- Lentigo maligna melanoma, 174-175
- Letter Cancellation test, for neuropsychological assessment, 513
- Lichen simplex chronicus, 197-198
- Life span, metabolic expenditure and, 2
- Light exposure, effect on fibroblasts, 29
- Light microscopy, of elastic fiber network of skin, 70-71

- of sun-induced aging, 225-226
- Lipid peroxidation, and aging process, 5
- Lipoproteins, measurement of, in hypertension, 728-729
- Lisinopril, cost of, 833
  - annual, 837
  - in renal disease, 822
- Liver, changes in, drug elimination with, 396
- Locomotion, generators of, 502
- Lubben Social Network Scale, of quality of life, 707
- Lymph nodes, dissection of, for malignant melanoma, 179
- Lymphoid tissue, skin-associated, 153
- Lymphokines, in aging, 151-158
  
- Magnesium, in hypertension, 661-662
- Maillard reaction, in aging, 12
- Malignant melanoma, clinical classification of, 173-175
  - clinicopathologic types of, 171
  - cutaneous, in older patient, 171-181
  - invasive, age-specific incidence of, 172
  - management of, 179-180
  - pathology of, 175-179
  - prognosis of, 175-179
- Mania, drug-induced, 446
  - with focal brain injury, 445-446
- Manometers, blood pressure, accuracy of, 721-722
- Material specificity, in memory assessment, 577-578
- Mattis Dementia Rating Scale, in dementia assessment, 535-536, 539, 553
- Meal patterns, assessment of, in dietary hypertension therapy, 778
- Medical history, in hypertension, 726-728
- Medical illness, and depression, 445
- Medications, and impotence, 309
- Melanin(s), biologic value of, 105-106
  - production of, in nevi, 100
- Melanocytes. *See also* *Pigment cells*.
  - biologic value of, 105-106
  - dermal, in postnatal life, 94-95
  - effect of growth factors on, 28
  - epidermal, during embryogenesis, 95-97
  - lives of, 91-108
  - origin of, 91-93
- Melanoma, malignant. *See* *Malignant melanoma*.
- Memory, anterograde vs retrograde, 566
  - assessment of, 565-581. *See also* *Memory assessment*.
  - clinical disorders of, 568-573. *See also* *Memory impairment*.
  - definition of, 565
  - difficulties with, snoring and, 386
  - general vs delayed, on Wechsler Memory Scale-Revised, 616-619
  - in affect assessment, 442
  - interactions with sleep, in animals, 371-375
    - in older subjects, 414
  - psychometric tests for, characteristics of, 573-578
  - short-term vs long-term, 567
  - types of, 566-568
  - visual, measures of, in dementia assessment, 614-621
- Memory assessment, ecological, 583-594
  - findings in, 591-593
  - method of, 585-586
  - results in, 586-591
  - subjects in, 585-586
  - test battery for, 587
  - material specificity in, 577-578
  - on Wechsler Memory Scale-Revised, 616
- Memory impairment, age-associated, definition of, 584
  - assessment of, 576-577
  - denial of, in dementia, 480
  - diagnosis of, 576
  - global vs specific, 569
  - in Alzheimer's disease, 533
  - psychogenic, 572
- Mental function, areas for testing, 547
- sleep disturbances and, 384
- Mental status assessment, 545-564
  - approaches to, 478-479
  - brief examination for, 548-552
  - in independent living skills assessment, 463-464
- Mental Status Questionnaire, in dementia, 535
- Mental tracking, decreased, in dementia, 492
- Metabolic alkalosis, in hypertension, 757
- Metabolic expenditure, and life span, 2
- Metamemory, assessment of, 481
- Metanephrines, in hypertension, 667, 757
- Methyldopa, cost of, 833
  - annual, 837
  - for hypertension, 809
  - effect on concomitant disease, 700
  - quality of life with, 710-711
- Methylxanthines, and drug-induced insomnia, 398-399
- Metoprolol, cost of, 833
  - for hypertension, 806-807
  - hydrochlorothiazide vs, 695
  - quality of life with, 706, 710
  - side effects of, 696
- Mice, age-related sleep changes in, 365-366
- Microvasculature, changes in, age-related, 78-84
  - microscopy of, 80-84
  - of skin, changes in, physiologic, 117-118
  - with phototaging, 237

- Milia, colloid, 230-231
- Mini-Mental Status Examination, administration of, 549-550
- correlation with Alzheimer's Disease Assessment Scale, 556
- for cognitive deficit measurement, 522
- in dementia, 492, 535
- of quality of life, 708
- Minnesota Multiphasic Personality Inventory, for personality assessment, 450-451
- Minoxidil, adverse effects of, 693
- cost of, 833
- effect on concomitant disease, 700
- Misplaced Objects Test, for ecological memory assessment, 587
- Mongolian blue spot, 95
- Monoamine oxidase inhibitors, for depression-associated sleep disturbances, 269
- Monoclonal gammopathies, age-related, 150
- Mood, assessment of, 441-459
- recent developments in, 452-454
- strategies for, 448-450
- changes in, in disease states, 444-448
- Motor activity, feedback component of, 503
- goal-driven, 502
- hierarchical organization of, 500-503
- Motor testing, effect of depression on, 506-507
- Multi-Score Depression Inventory, 507
- Myocardial infarction, antihypertensive agents in, 814-815
- Myoclonus, nocturnal, with sleep apnea, 356-357
- Nadolol, cost of, 833
- in renal disease, 821
- Nail changes, in elderly, 207-208
- Name-Face Association Test, for ecological memory assessment, 587, 589
- Napping, increase with age, 278
- Narcolepsy, performance deficits in, 387
- National High Blood Pressure Education Program, 675
- Nervous system, sympathetic, role in hypertension, 663, 666-668
- Neural crest, formation of, 92-93
- pigment cell origin in, 91-93
- Neurobehavioral Cognitive Status Examination, for patient classification, 548
- of cognitive function, 554
- Neurodegenerative diseases, similarities to Alzheimer's disease, 430
- Neurofibrillary tangles, in Alzheimer's disease, 429
- association with cognitive deficits, 431-433
- Neurologic disorders, age-related, 507-509
- and impotence, 308-309
- Neuropsychologic evaluation, new developments in, 425-632
- Neuropsychologic function, and sleep, 381-394
- assessment of, age effects on, 596-601
- recent developments in, 452-456
- impairment of, sleep apnea and, 353-354
- Neuropsychology, role in Alzheimer's disease, 425-428
- Neuropsychology Behavior and Affect Profile, for personality assessment, 454-455
- Neurotransmitters, in Alzheimer's disease, 434-438
- Nevus(i), 100-103
- acquired, 101-103
- blue, 94
- congenital, 101-102
- Nifedipine, cost of, 833
- annual, 837
- for hypertension, 807
- in coronary artery disease, 816
- in renal disease, 822-823
- Nodular elastoidosis, 230-231
- Nodular melanoma, 173
- Nonenzymatic glycosylation, in aging, 12-13
- Nonfibroblast lines, senescence in, 25-26
- Nonmelanoma skin cancers, in elderly, 161-170
- Nonverbal memory items, for cognitive measurement scales, 526-527
- Norepinephrine, circulating levels of, in hypertension, 661, 663, 666
- Normative tables, for test evaluation, problems with, 574
- Nortriptyline, for late-life depression, findings in, 264
- Nursing home patients, sleep problems in, 354-355
- Nutrition counseling, individualized, for hypertension therapy, 776, 783-784
- Obesity, and hypertension, 658-659, 771
- Obsession-compulsion, and performance speed, 510
- Older adult, assessment of, special needs in, 595-596
- hypertension in, evaluation of, 717-732
- mood assessment in, 442-443
- neuropsychological assessment of, 509-514
- psychomotor assessment of, 499-515
- use of Halstead-Reitan Test Battery with, 595-610
- Older American Research and Service Center scale, for independent living skills assessment, 469

- Oral cavity, nevi in, 103-104
- Oral hygiene, assessment of, in dietary hypertension therapy, 778
- Ota, nevus of, 94-95
- Outlook, effect of appearance on, 220
- Overweight, and hypertension, 658-659, 771
- Oxprenolol, quality of life with, 711
- Oxygen, concentrations of, effect on fibroblasts, 29
- consumption of, in wound healing, 186
- Oxygen radicals, in cutaneous malignancy, 106
- Pain, perception of, age-related decline in, 119-120
- Parkinson's disease, depression in, 444-445
- Pemphigoid, bullous, 193
- Penile tumescence, nocturnal, normal, 303-304
- Perceptual discrimination, impaired, in Alzheimer's disease, 534
- Performance Activities of Daily Living Scale, for independent living skills assessment, 469-470
- Performance efficiency, tests of, correlations with REM sleep, 382
- with sleep loss, 405, 413-416
- Periodic breathing, in sleep apnea, 317
- Peripheral vascular system, in hypertension, 658, 663
- Personality, assessment of, 441-459
- recent developments in, 454-456
- strategies for, 450-452
- changes in, with central nervous system dysfunction, 446-448
- effect of normal aging on, 443
- Pheochromocytoma, and hypertension, 754, 757
- Photoaging, 235-251
- action spectrum of, experimental studies in, 239-246
- aging vs, histologic comparisons of, 235-239
- prevention of, 246-247
- solar-simulating radiation and, 242-243
- therapy for, 247-249
- ultraviolet and, 239-243
- Physical activity, assessment of, in dietary hypertension therapy, 778
- Physical examination, in hypertension, 726-728
- Physical Self-Maintenance Scale, for independent living skills assessment, 468-469
- Physical status, effect on neuropsychological testing, 442, 596
- Pigment cells. See also *Melanocytes*.
- dermal, 93-97
- during embryogenesis, 93-94
- epidermal, postnatal, 96-98
- in hair, in postnatal life, 99-100
- lives of, 91-108
- Pigmentation, irregular, with sun exposure, 229
- Planning items, for cognitive measurement scales, 526-527
- Plasma renin activity, in renovascular hypertension, 665-666, 761-762
- Polyp, fibroepithelial, 190-191
- Population, aging of, dermatologic implications of, 41-51
- Posture, and blood pressure, 720, 722
- Potassium, for hypertension, 770
- in hypertension, 661-662, 728
- Potassium chloride, cost of, annual, 837
- Pragnosia, following brain injury, 448
- Prazosin, cost of, 833
- for hypertension, 808
- in renal disease, 822
- Premature aging, of skin, 235-251
- Procollagen, synthesis of, 130
- Proline, in collagen polypeptides, 129
- Prolyl hydroxylase, catalytic activity of, in aging skin, 136
- Propranolol, blood lipid changes in, 798
- cost of, 833
- following myocardial infarction, 814-815
- for hypertension, 806-807
- quality of life with, 710-711
- Protein oxidation, and aging process, 5
- Proverb interpretation, for judgment assessment, 489
- Prurigo nodularis, 197-198
- Pruritus, 195-196
- Pseudodementia, depressive, sleep changes in, 264
- Pseudohypertension, 645
- identification of, 725
- PSMSADL scales, for independent living skills assessment, 468-469
- Psychoeducational therapy, for depression-associated sleep disturbances, 269
- Psychologic disorders, and impotence, 310
- Psychometrics, relationships to EEG-defined sleep stages, 381-384
- Psychomotor performance, age-related behavioral slowing of, 504-506
- age-related neuropsychological changes in, 504-509
- assessment of, 499-515
- neuroanatomical correlates of, 503-504
- with sleep loss, 405
- Psychotherapy, for depression-associated sleep disturbances, 268

- Pulmonary disease, chronic obstructive, antihypertensive agents in, 818
- PULSES Profile, for independent living skills assessment, 466
- Purdue Pegboard, for neuropsychological assessment, 512
- Purpose, in psychomotor activity, 501
- Purpura, senile, 202
- Quality of life, antihypertensive therapy and, 696-697, 703-715  
as outcome of therapy, 704, 705  
definition of, 703-706  
domains of, 707  
measures of, 704, 706-709
- Race, association with blood pressure, 643-644
- Racemization, amino acid, in aging, 11-12
- Radiation, and photoaging, 242-246
- Rate-of-living theory, of biologic aging, 2-4
- Rats, circadian sleep-wake rhythm in, 364-365
- Raven Progressive Matrices, for judgment assessment, 489
- Reaction time, in ecological memory assessment, 587  
slowing of, in neurologic disease, 508  
with aging, 504  
with sleep loss, 414-415
- Reasoning, investigation of, in dementia, 495
- Reciprocal tapping test, for neuropsychological assessment, 514
- Relaxation training, for hypertension, 795
- Reliability, in cognitive deficit measurement, 523-524  
in Halstead-Reitan Test Battery, 603-604
- REM sleep, 409-412  
and penile erections, 303  
in depression, 260-261  
in older subjects, 281  
interaction with slow-wave sleep, 417  
latency of, in sleep loss recovery, 411, 413
- Renal arteriography, in renovascular hypertension, 762
- Renal disease, and hypertension, 651, 658, 754, 759-760, 763  
antihypertensive agents in, 820-823
- Renin, role in hypertension, 665-666, 761-762
- Renovascular hypertension, 760-761  
therapy for, 763-765
- Reserpine, cost of, 833  
annual, 837  
for hypertension, 808-809
- Respiratory disturbance, index of, 350  
sleep-related, effect of drugs on, 400-401  
neuropsychologic impairment in, 389  
psychometric correlates of, 384-388
- Rete pegs, retraction of, in aging skin, 55
- Retinal epithelium, pigment cells of, 103-105
- Retinoic acid, for photoaged skin, 247-249
- Rhinophyma, 200-201
- Rotary Pursuit, for neuropsychological assessment, 513
- Rough endoplasmic reticulum, electron microscopy of, 82
- S-Transferases, in cellular protection against oxidative free radical damage, 9
- Sacral spot, 95
- Salt consumption, and hypertension, 659-661, 728, 771-772, 779
- Savings scores, on Wechsler Memory Scale-Revised, 619-621
- Scales of Independent Behavior, for independent living skills assessment, 471
- Schiff base, formation of, in aging, 12
- Sebaceous gland, changes in, 109-114  
hyperplasia of, 192
- Seborrheic dermatitis, prevalence rates for, 47  
with declining sebum secretion rate, 113-114
- Seborrheic keratoses, 189-191
- Sebum secretion, changes in, 109-114  
rate of, decline with age, 112-114  
measurement of, 109-110  
variability of, 110-113  
ultimate levels of, 113
- Selective Reminding Test, for ecological memory assessment, 587, 589-590
- Self-examination, for malignant melanoma, 179
- Self-maintenance activities, assessment of, 462
- Self-perception, appearance and, 215-217  
cosmetic use and, 219-220
- Senile plaques, in Alzheimer's disease, 429  
association with cognitive deficits, 431-433
- Sensory deficits, in neuropsychological testing, 596  
with aging, 505
- Severe Impairment Battery, for severe dementia, 538
- SHEP. See *Systolic Hypertension in the Elderly Program*.
- Shift work, intolerance to, 343
- Shingles, 201-202
- Shipley Institute of Living Scale, for judgment assessment, 489

- Short Portable Mental Status Questionnaire, administration of, 550-552  
in dementia, 535
- Sickness Impact Profile, of quality of life, 708
- Similarities subtest, for judgment assessment, 490
- Skills, assessment of, in dietary hypertension therapy, 778
- Skin, aged, abnormalities in, 69-90, 139-143  
light microscopic appearance of, 54  
morphology of, 53-67  
physiologic changes in, 115-125  
atrophy of, with sun exposure, 230, 237  
barrier properties of, 115-117  
cancers of, nonmelanoma, in elderly, 161-170  
dermal/epidermal surface of, electron microscopic appearance of, 55  
geometric patterns of, 54  
grafting of, and reversal of sun-induced aging, 227  
immune function of, age-related alteration in, 152-158  
microvasculature of, changes in, physiologic, 117-118  
with photoaging, 237  
normal, connective tissue biochemistry of, 128-133  
percutaneous adsorption by, 116-117  
pigment cells of, 93-97  
problems of, common, in elderly, 189-211  
prevalence rates for, 46-48  
tags of, 190-191  
tumors of, benign, 189-192  
prevalence rates for, 46  
vulnerability of, with aging, 119-120
- Sleep, amount of, extremes of, 278  
methods of determining, 277  
and aging, in animals, 363-379  
changes in, age-related, 275-287  
in animals, 363-369  
thermoregulation in, 368  
interpretation of, 283-284  
circadian rhythm in, in animals, 369-370  
complaints about, subjective reports of, 347-348  
continuity of, 279  
and memory, in animals, 371  
in rats, 364-365  
cycles of, in depression, 260  
deprivation of. *See Sleep deprivation.*  
dimensions of, 275-276  
disorders of, disturbances vs, 285  
drugs and, 395-404  
epidemiology of, 347-362  
implications of, 284-286  
disruption of, as sleep deprivation, 416-417  
disturbances of, and mental function, 285, 384  
duration of, in rats, 364  
total, 407-408  
EEG, in late-life depression, 260-262  
fragmentation of, in sleep apnea, 322  
in Alzheimer's disease, 289-299  
in late life, 259-273  
in nursing homes, 354-355  
interactions with cognitive function, in animals, 371-375  
leg movements in, 356-357, 401-402, 412  
loss of. *See Sleep loss.*  
neuropsychologic function and, 381-394  
nocturnal, characteristics of, 283  
onset latency of, 279, 408-410  
test of, 348  
paradoxical, and performance, in animals, 372-374  
patterns of, 276-280  
physiologic function and, in animals, 368-369  
REM. *See REM sleep.*  
slow-wave, interaction with REM sleep, 417  
stages of, 280-281, 407-413  
baseline and recovery, 407  
EEG-defined, 381-384  
psychometric correlates of, 382  
structure of, 280-281  
subjective evaluations of, 281-283  
timing of, 278  
transient arousal from, 409
- Sleep apnea, 350-353  
and neuropsychological impairment, 353-354  
arrhythmias with, 322  
clinical features of, 321-322  
cognitive impairment with, 354  
definition of, 315  
frequency of, 317-318  
in elderly, 315-329  
prevalence of, 351-353  
mortality in, 323, 355-356  
pathogenesis of, 317-320  
polygraphic tracings of, 316  
prevalence of, 316-317, 351-353  
psychometric correlates of, 385  
syndrome of, in late-life depression, 267  
therapy for, 324-325  
types of, 350  
with dementia, 353
- Sleep deprivation, in dementia, 265-266  
in depression, 265-266, 417  
REM sleep response to, 262  
sleep disruption as, 416-417
- Sleep diary, correlation with self estimates, 276



- Sleep-disordered breathing, clinical evaluation of, 323-324  
in depression, 267
- Sleep disorders, in elderly, 259-420
- Sleep log, correlation with self estimates, 276
- Sleep loss, and sleep onset latency, 408-410  
in aging, 405-420  
implications of, 417-418  
performance in, 413-416  
recovery from, 407-413  
studies of, 406
- Sleep/wake patterns, circadian, in rats, 365  
fragmentation with aging, 367  
in Alzheimer's disease, 289-299
- Sleepiness, daytime, drug-induced, 402  
excessive, 348-349  
drug-induced, and aging, 397-398  
sleep loss and, 406
- Slow-wave sleep, interaction with REM sleep, 417
- Smoking, and blood pressure, 722  
and impotence, 305
- Snoring, and memory difficulties, 386  
in sleep apnea, 321  
prevalence of, 349-350  
with airway obstruction, 349
- Social support, assessment of, in dietary hypertension therapy, 778
- Socializing, effect of appearance on, 220
- Sodium, and hypertension, 659-661, 728, 771-772, 779
- Sodium restriction, for hypertension, 770  
benefits of, 780-781  
efficacy of, 772-775  
essential elements of, 776-777  
failure prevention in, 783  
guidelines for, 775-780  
precautions in, 780-782
- Sodium sensitivity, in elderly, 660
- Solar elastosis, 223
- Solar-simulating radiation, and photoaging, 242-243
- Somatostatin, decreased, in Alzheimer's disease, 437
- Speed, performance, neuropsychological assessment of, 509-510
- Sphygmomanometers, dimensions of, 721
- Sphygmomanometry, ambulatory blood pressure monitoring vs, 739-741
- Spider veins, 203
- Squamous cell carcinoma, invasive, progression of actinic keratoses to, 162-166
- SRIF, correlation with dementia severity, in Alzheimer's disease, 437
- Standardization, in testing, definition of, 477-478
- Statin, in nonreplicating cells, 30
- Stimulants, and drug-induced insomnia, 398-399  
and drug-induced sleepiness, 397
- Stomatitis, angular, 199-200
- Stratum corneum, barrier properties of, 115  
normal turnover of, 121-123
- Stress management training, for hypertension, 795  
in Heartsavers Lifestyle Management Program, 796
- Stroke, antihypertensive agents in, 823  
depression in, 445  
hypertension and, 651  
with snoring, 350
- Structured Activities of Independent Living Scale (SAILS), for Alzheimer's disease, 428, 472
- Sun, aging of skin by, 223-233  
exposure to, and skin cancer, 162  
effect on fibroblasts, 29
- Sunscreen, prevention of photoaging with, 246-247
- Superficial spreading melanoma, 173
- Superoxide dismutase, in cellular protection against oxidative free radical damage, 6
- Symbol digit modalities, neuropsychological assessment of, 511
- Systolic Hypertension in the Elderly Program, 676  
quality of life measurements in, 712
- Tactual Performance Test, age-related decrements in, 599-600
- Telangiectasia, with sun exposure, 229-230
- Telephone Test, for ecological memory assessment, 587
- Temperature, ambient, effect on blood pressure, 645  
free-running rhythm of, 338-339  
oral, 332  
rectal, 335  
regulation of, and age-related sleep changes, in animals, 368
- Temporal lobe lesions, and amnesia, 571
- Terazosin, cost of, 833
- Test construction, principles of, in mental status examinations, 546
- Testing time, in Halstead-Reitan Test Battery, 602-603
- Thematic Apperception Test, for insight assessment, 486
- Theophylline, and drug-induced insomnia, 398-399
- Thermoregulation, and age-related sleep changes, in animals, 368
- Thiazides, adverse effects of, 693  
effect on concomitant disease, 699  
in coronary artery disease, 815  
quality of life with, 710

- Thymus, relationship to skin, in immune response, 153
- Time cues, and circadian rhythm entrainment, 342
- Timolol, following myocardial infarction, 814-815
- Tocopherol, in cellular protection against oxidative free radical damage, 9
- Topographic Memory Test, for ecological memory assessment, 587
- Trailmaking Test, age-related decrements in, 599  
for neuropsychological assessment, 511-512
- Triamterene, cost of, annual, 837
- Triazolam, effect on sleep-related respiratory disturbance, 400
- Tricyclic antidepressants, and periodic leg movements in sleep, 401  
for depression-associated sleep disturbances, 268  
for sleep apnea, 325
- Trimazosin, in renal disease, 822
- Ulcers, stasis, 203-204
- Ultraviolet, and photoaging, 239-243  
effect on epidermal immune function, 154  
wavelengths affecting skin, 231-232
- Upper airway, obstruction of, and sleep apnea, 317, 319-320  
clinical significance of, 322-323
- Urate, in cellular protection against oxidative free radical damage, 10
- Uric acid, in hypertension, 728  
with antihypertensive therapy, 694
- Urinalysis, in hypertension, 728
- Uvulopalatopharyngoplasty, for sleep apnea, 325
- Validity, criterion-related, in mental status examinations, 547  
in Halstead-Reitan Test Battery, 604-606
- Vanillylmandelic acid, urinary, in hypertension, 757
- Vascular changes, and impotence, 305-308  
functional, and hypertension, 663-665  
structural, with aging, 662-663  
isolated systolic hypertension in, 665-666
- Vascular disorders, depression in, 444  
in elderly, 202-204
- Vasoconstriction, in hypertension, 664
- Vasodilators, adverse effects of, 693  
cost of, 833  
for hypertension, 808  
effect on concomitant disease, 700  
quality of life with, 710
- Veil cells, in aging skin, 87
- Venous lakes, 202
- Ventilatory drive, abnormalities of, and sleep apnea, 318
- Venule, postcapillary, in aging skin, 87-88  
thickening of, 80  
thinning of, 83
- Verapamil, cost of, 833  
annual, 837  
for hypertension, 807  
in coronary artery disease, 816  
in renal disease, 822-823
- Verbal memory items, for cognitive measurement scales, 525-526  
on Wechsler Memory Scale-Revised, 616
- Verbal reasoning items, for cognitive measurement scales, 525
- Visual Analogue Mood Scales, for mood assessment, 453-454
- Visual memory, assessment of, in dementia assessment, 614-621
- Visual Reproduction Test, of Wechsler Memory Scale-Revised, intrusion errors on, 622-624
- Visual-spatial reasoning items, for cognitive measurement scales, 526
- Vocabulary items, for cognitive measurement scales, 524-525
- Water loss, transepidermal, 116
- Wechsler Adult Intelligence Scale-Revised, elderly sample sizes in, 574
- Wechsler Memory Scale-Revised, attention vs memory on, 613  
characteristics of, 575  
comparison with original scale, 612-613  
difference scores on, 617-619  
floor effects of, 628  
for differentiating dementias, 611-632  
immediate vs delayed memory on, 613  
index scores on, 613, 616-617  
intrusion errors on, as marker of dementia, 621-627  
normative data for, limitations in, 629  
savings scores on, 619-621  
subject groups of, 616-617  
verbal bias of, 628
- Weight reduction, for hypertension, 770  
benefits of, 780-781  
efficacy of, 772-775  
essential elements of, 776-777  
failure prevention in, 783  
guidelines for, 775-780  
precautions in, 780, 782-783  
for sleep apnea, 325  
in Heartsavers Lifestyle Management Program, 796

Well-being, appearance and, in elderly,  
214-218  
Wernicke-Korsakoff syndrome, amnesia in,  
570  
Wisconsin Card Sorting Test, for judgment  
assessment, 489  
Wound healing, aging and, 120-121, 183-  
189

biosynthetic activity in, 186-187  
cellular activities in, 185-186  
clinical observations in, 183-185  
Wrinkles, in elderly, 208-209

Zung depression scale, for mood assessment,  
449, 507

